MYOV

Myovant Sciences Ltd. [MYOV] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MYOV Stock Summary

In the News

MYOV Financial details

Company Rating
-
Market Cap
2.62B
Income
-183.77M
Revenue
379.11M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
579
Optionable
No
Shortable
Yes
Earnings
25 Jul 2023
P/E
-14.22
Forward P/E
-
PEG
4.37
P/S
6.92
P/B
-4.68
P/C
-
P/FCF
-9.69
Quick Ratio
1.3
Current Ratio
1.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.91
EPS next Y
-
EPS next Q
-
EPS this Y
-21.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-4.38%
EPS Q/Q
25.53%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-46%
ROE
36%
ROC
-0.93%
Gross Margin
73%
Oper. Margin
-39%
Profit Margin
-48%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.67-27.06
52W High
-0.07%
52W Low
+285.43%
RSI
-
Rel Volume
2.07
Avg Volume
1.09M
Volume
2.26M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-0.04%
-
-
-
-
Beta
2.15468
-
-
Volatility
0%, 0%
Prev Close
0%
Price
26.98
Change
-0.04%

Something similar

Top by Market Cap
APC.DE
GOOG
ABEA.DE
LLY.DE
3V64.DE
Same Sector
PETV
ACIU
MMNFF
118000.KS
CTXR
Check Those
SBN.TO
1877.HK
UNIR
000616.SZ
017390.KS
Similar Market Cap
002999.SZ
NUV
2302.TW
002722.SZ
CCA.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 1.09M
  • Market Capitalization 2.62B
  • Employee 579
  • CEO Mr. David C. Marek
  • Headquarters London,GB
  • IPO Date 2016-10-27
  • Website https://myovant.com

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.